Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Head & Neck 2Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 4Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Turcot syndrome 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Gynecologic Cancers 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Cyclophosphamide 8Gemcitabine 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Immune Checkpoint Inhibitors × Gynecologic × Clear all
NCT03989336 2024-07-15

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Chinese PLA General Hospital

Phase 2 Completed
84 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡